Bevacizumab

(Avastin®)

Bevacizumab

Latest News

loading GIF

Drug updated on 4/17/2024

Dosage FormInjection (intravenous; 100 mg/4 mL [25 mg/mL] or 400 mg/16 mL [25 mg/mL])
Drug ClassVascular endothelial growth factor inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil based chemotherapy for first- or second-line treatment.
  • Indicated for the treatment of metastatic colorectal cancer, in combination with fluoropyrimidineirinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
  • Indicated for the treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.
  • Indicated for the treatment of recurrent glioblastoma in adults.
  • Indicated for the treatment of metastatic renal cell carcinoma in combination with interferon alfa.
  • Indicated for the treatment of persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.
  • Indicated for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection.
  • Indicated for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens.
  • Indicated for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease.
  • Indicated for the treatment of hepatocellular Carcinoma (HCC): in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Bevacizumab (Avastin) is indicated for the treatment of various types of cancer, including metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, glioblastoma, and others. It is often used in combination with chemotherapy or other targeted agents to improve outcomes.
  • A total of 164 systematic reviews/meta-analyses focused on evaluating the safety and effectiveness of bevacizumab across multiple studies and different types of cancers.
  • When combined with chemotherapy, bevacizumab significantly improves progression-free survival across several types of cancers such as metastatic colorectal cancer and NSCLC.
  • In NSCLC specifically, using bevacizumab alongside EGFR-TKIs or as a maintenance therapy approach shows promise in improving patient outcomes without significantly increasing severe adverse events.
  • For treating metastatic colorectal cancer specifically, combining bevacizumab with chemotherapy has been shown to improve overall survival rates compared to just using chemotherapy alone. However, this does come at an increased risk for specific adverse events like hypertension and proteinuria.
  • The effectiveness varies greatly depending on factors such as the type of cancer being treated; whether it is first-line vs maintenance therapy; along with the genetic/molecular profile specifics related to each individual tumor - e.g., RAS status in colorectal cases or PD-L1 expression levels in NSCLC patients.
  • In terms of direct comparisons between Avastin and other targeted therapies/immunotherapies: these highlight complexities within treatment landscapes where Avastin can show comparable/superior effectiveness, especially if used within combination regimens.
  • The choice between Avastin and other drugs will depend upon numerous factors, including but not limited to: type/stage/molecular characteristics associated with the disease plus patient tolerance towards potential side effects.
  • Accordingly, the application within clinical settings requires careful consideration towards individual patient's clinical characteristics, disease factors, and potential risks associated with treatment.
  • The role of Avastin in combination with emerging therapies, including immune checkpoint inhibitors, is an evolving area of research that could redefine treatment protocols for several cancer types.

Product Monograph / Prescribing Information

Document TitleYearSource
Avastin (bevacizumab) Prescribing Information.2022Genentech Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of trifluridine/tipiracil-containing combinations in colorectal cancer and other advanced solid tumors: a systematic review.2024The Oncologist
Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis.2024BMC Gastroenterology
Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis.2024Therapeutic Advances in Medical Oncology
Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis.2024Frontiers in Oncology
Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysis.2024Diagnostic and Interventional Radiology
Reassessing the efficacy of bevacizumab in newly diagnosed glioblastoma: a systematic review and external pseudodata-based analysis.2024Neuro-Oncology Advances
The efficacy of bevacizumab combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials.2024Frontiers in Pharmacology
Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis.2024Frontiers in Pharmacology
Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.2024BMC Geriatrics
Evaluation of bevacizumab biosimilar on wound healing complications in patients with colorectal cancer undergoing endoscopic mucosal resection: a systematic review and meta-analysis in anorectal medicine.2024International Wound Journal
Efficacy of anti-VEGF drugs based combination therapies in recurrent glioblastoma: systematic review and meta-analysis.2024Current Reviews in Clinical and Experimental Pharmacology
A systematic review of nanomedicine in glioblastoma treatment: clinical efficacy, safety, and future directions.2023Brain Sciences
Efficacy and safety of bevacizumab for treating glioblastoma: a systematic review and meta-analysis of phase II and III randomized controlled trials.2023Cancer Investigation
Comparative efficacy and safety of systemic therapy for advanced hepatocellular carcinoma: a systematic review and network meta-analysis.2023Frontiers in Oncology
Atezolizumab in combination with bevacizumab for the management of patients with hepatocellular carcinoma in the first-line setting: systematic literature review and meta-analysis.2023Liver Cancer
Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: a meta-analysis.2023PLoS One
Proteasome inhibitors in the treatment of nonsmall cell lung cancer: a systematic review of clinical evidence.2023Health Science Reports
Comparing efficacy of erlotinib and bevacizumab combination with erlotinib monotherapy in patients with advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.2023Diseases
Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.2023Therapeutice Advances in Chronic Disease
Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis.2023Frontiers in Oncology
Bevacizumab treatment for low-grade serous ovarian cancer: a systematic review.2023Current Oncology
Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.2023Clinical and Experimental Hepatology
Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity.2023Journal of Neuro-Oncology
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.2023EClinicalMedicine
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.2023European Journal of Medical Research
Comparison between different treatment regimens of vascular targeting drug to malignant pleural effusion in patients with lung cancer: a Bayesian network meta-analysis.2023Medicine
Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.2023Frontiers in Pharmacology
Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis.2023BMC Cancer
Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: a systematic review.2023Frontiers in Pharmacology
Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis.2023Medicine
Different doses of bevacizumab in combination with chemotherapy for advanced colorectal cancer: a meta-analysis and Bayesian analysis.2023International Journal of Colorectal Disease
Efficacy and safety of pharmacotherapy for recurrent high-grade glioma: a systematic review and network meta-analysis.2023Frontiers in Pharmacology
Targeted therapies in patients with newly diagnosed glioblastoma-a systematic meta-analysis of randomized clinical trials.2023International Journal of Cancer
A systematic review and meta-analysis of trifluridine/tipiracil plus bevacizumab for the treatment of metastatic colorectal cancer: evidence from real-world series.2023Current Oncology
Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: a systematic review and network meta-analysis.2023PLoS One
Treatment options for recurrent platinum-resistant ovarian cancer: a systematic review and Bayesian network meta-analysis based on RCTs.2023Frontiers in Oncology
Impact of neoadjuvant chemotherapy on post-hepatectomy regeneration for patients with colorectal cancer liver metastasis - systematic review and meta-analysis.2023European Journal of Surgical Oncology
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: a systematic literature review and network meta-analysis.2023Lung Cancer
Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: a Bayesian network meta-regression analysis.2023Frontiers in Oncology
First-line systemic therapies for advanced hepatocellular carcinoma: a systematic review and patient-level network meta-analysis.2023Liver Cancer
Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis.2023Therapeutic Advances in Medical Oncology
Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis.2023Frontiers in Immunology
Immune-based combinations versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: a meta-analysis.2023Current Oncology
Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials.2023Annals of Medicine
Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: a network meta-analysis.2022Frontiers in Oncology
Efficacy and safety of metronomic chemotherapy in maintenance therapy for metastatic colorectal cancer: a systematic review of randomized controlled trials.2022Medicine
A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: a Bayesian network meta-analysis.2022Frontiers in Pharmacology
Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.2022Acta Oncologica
A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.2022Frontiers in Immunology
Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis.2022Therapeutic Advances in Medical Oncology
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis.2022International Journal of Gynecological Cancer
Efficacy and safety of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor combination therapy as first-line treatment for patients with advanced EGFR-mutated, non-small cell lung cancer: a systematic review and bayesian network meta-analysis.2022Cancers
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network metanalysis of phase III trials.2022European Journal of Cancer
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: a network meta-analysis of randomized sorafenib-controlled trials.2022Hepatology Communications
First- and second-line treatments for patients with advanced hepatocellular carcinoma in China: a systematic review.2022Current Oncology
Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis.2022Discover Oncology
Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab.2022Frontiers in Pharmacology
A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: the state-of-the-art.2022Frontiers in Oncology
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials.2022BMJ Open
Safety assessment on serious adverse events of targeted therapeutic agents prescribed for RAS wild-type metastatic colorectal cancer: systematic review and network meta-analysis.2022International Journal of Environmental Research and Public Health
Overall survival benefits of first-line treatments for asian patients with advanced epidermal growth factor receptor-mutated NSCLC harboring exon 19 deletion: a systematic review and network meta-analysis.2022Cancers
Clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with liver metastases: a network meta-analysis of nine randomized controlled trials.2022Cancer Research and Treatment
The utilization of bevacizumab in patients with advanced ovarian cancer: a systematic review of the mechanisms and effects.2022International Journal of Molecular Sciences
Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis.2022Translational Cancer Research
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.2022ESMO Open
Overall survival benefits of first-line treatments for Asian patients with advanced EGFR-mutated NSCLC harboring L858R mutation: a systematic review and network meta-analysis.2022JTO Clinical and Research Reports
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.2022European Journal of Cancer
First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: a Bayesian network meta-analysis of randomized controlled trials.2022Cancer Medicine
Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta-analysis.2022Journal of the National Cancer Institute
What is long-term survival and which first-line immunotherapy brings long-term survival for advanced wild-type non-small cell lung cancer: a network meta-analysis based on integrated analysis.2022Frontiers in Immunology
Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.2022BMC Cancer
Combined immunotherapy with chemotherapy versus bevacizumab with chemotherapy in first-line treatment of driver-gene-negative non-squamous non-small cell lung cancer: an updated systematic review and network meta-analysis.2022Journal of Clinical Medicine
A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer.2022Scientific Reports
Protective ostomies in ovarian cancer surgery: a systematic review and meta-analysis.2022Journal of Gynecologic Oncology
Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.2022Cochrane Database of Systematic Reviews
Efficacy and safety of systemic treatments among colorectal cancer patients: a network meta-analysis of randomized controlled trials.2022Frontiers in Oncology
Pretreatment ADC histogram analysis as a prognostic imaging biomarker for patients with recurrent glioblastoma treated with bevacizumab: a systematic review and meta-analysis.2022American Journal of Neuralradiology
The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: a meta-analysis of randomized controlled trials.2022Journal of Clinical Pharmacy and Therapeutics
Tolerability on serious adverse events of first-line bevacizumab and cetuximab for RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.2022Healthcare
Efficacy and safety of immunotherapy for cervical cancer-a systematic review of clinical trials.2022Cancers
Treatment patterns for advanced non-small cell lung cancer in the US: a systematic review of observational studies.2022Cancer Treatment and Research Communications
Risk and incidence of infection with bevacizumab in non-small-cell lung cancer patients: a meta-analysis.2022Oncology Research and Treatment
Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: a meta-analysis.2022Thoracic Cancer
Efficacy and safety of bevacizumab biosimilars compared with reference biologics in advanced non-small cell lung cancer or metastatic colorectal cancer patients: a network meta-analysis.2022Frontiers in Pharmacology
The utilization of bevacizumab in patients with advanced ovarian cancer: a systematic review of the mechanisms and effects.2022International Journal of Molecular Sciences
Pneumothorax as a complication of bevacizumab-containing chemotherapy: a systematic review of case reports.2022Cureus
The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: a systematic review and meta-analysis.2021Medicine
Effectiveness and safety of adding bevacizumab to platinum-based chemotherapy as first-line treatment for advanced non-small-cell lung cancer: a meta-analysis.2021Frontiers in Medicine
Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: a meta-analysis.2021Thoracic Cancer
The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: a meta-analysis of randomized controlled trials.2021Journal of Clinical Pharmacy and Therapeutics
Bevacizumab treatment of radiation-induced brain necrosis: a systematic review.2021Frontiers in Oncology
Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: a systematic review and meta-analysis.2021Medicine
The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: a systematic review and meta-analysis.2021Gynecologic Oncology
First-line systemic treatment strategies for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis of randomized clinical trials.2021Frontiers in Oncology
Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis.2021BMJ Open
Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis.2021JAMA Network Open
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO.2021ESMO Open
A comparison of bevacizumab plus TAS-102 and TAS-102 monotherapy for metastatic colorectal cancer: a systematic review and meta-analysis.2021Frontiers in Oncology
Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: a systematic review.2021World Journal of Gastrointestinal Oncology
Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis.2021European Review for Medical and Pharmacological Sciences
Risk of thrombo-embolic events in ovarian cancer: does bevacizumab tilt the scale? A systematic review and meta-analysis.2021Cancers
The safety and effectiveness of bevacizumab in the treatment of nonsquamous non-small-cell lung cancer: a meta-analysis of randomized controlled trials.2021BioMed Research International
Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020).2021Gastroenterology
Non-surgical management of advanced hepatocellular carcinoma: a systematic review by Cancer Care Ontario.2021Canadian Liver Journal
Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: a systematic review and meta-analysis.2021Medicine
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: a meta-analysis.2021Cancer
Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: a systematic review and network meta-analysis.2021Journal of Thoracic Oncology
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: a meta-analysis of individual patients' data from 3 phase III studies.2021Cancer Treatment Reviews
Effectiveness and safety of adding bevacizumab to platinum-based chemotherapy as first-line treatment for advanced non-small-cell lung cancer: a meta-analysis.2021Frontiers in Medicine
Optimal maintenance strategy for first-line oxaliplatin-containing therapy with or without bevacizumab in patients with metastatic colorectal cancer: a meta-analysis.2021Cancer Research and Treatment
Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review.2021Acta Neurochirurgica
The role of immunotherapy in hepatocellular carcinoma: a systematic review and pooled analysis of 2,402 patients.2021Oncologist
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.2021Therapeutic Advances in Medical Oncology
Selection of first-line systemic therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials.2021World Journal of Gastroenterology
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.2021Cochrane Database of Systematic Reviews
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.2021Cochrane Database of Systematic Reviews
Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials.2021BMC Cancer
Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma.2021Neuro-Oncology Advances
Optimal therapies for recurrent glioblastoma: a Bayesian network meta-analysis.2021Frontiers in Oncology
Comparison of efficacy of systemic therapies in advanced hepatocellular carcinoma: updated systematic review and frequentist network meta-analysis of randomized controlled trials.2021Journal of Hepatocellular Carcinoma
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.2021Cochrane Database of Systematic Reviews
Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis.2021BMC Cancer
A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.2021Journal of Clinical Pharmacy and Therapeutics
Optimizing survival and the changing landscape of targeted therapy for intermediate and advanced hepatocellular carcinoma: a systematic review.2021Journal of the National Cancer Institute
Effectiveness of lomustine combined with bevacizumab in glioblastoma: a meta-analysis.2021Frontiers in Neurology
Network meta-analysis of first-line systemic treatment for patients with metastatic colorectal cancer.2021Cancer Control
The efficacy and safety of adding bevacizumab in neoadjuvant therapy for locally advanced rectal cancer patients: a systematic review and meta-analysis.2021Translational Oncology
Role of antiangiogenic agents combined with EGFR tyrosine kinase inhibitors in treatment-naive lung cancer: a meta-analysis.2021Clinical Lung Cancer
AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma.2021Gastroenterology
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.2020Cochrane Database of Systematic Reviews
Clinical and pathological characteristics of metastatic renal cell carcinoma patients needing a second-line therapy: a systematic review.2020Cancers
Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.2020JAMA Oncology
Is there an efficacy-effectiveness gap between randomized controlled trials and real-world studies in colorectal cancer: a systematic review and meta-analysis.2020Translational Cancer Research
Targeted therapy for metastatic renal cell carcinoma.2020Cochrane Database of Systematic Reviews
Comparison of first-line treatments for patients with extensive-stage small cell lung cancer: a systematic review and network meta-analysis.2020JAMA Network Open
First-line treatment of metastatic renal cell carcinoma in the immuno-oncology era: systematic review and network meta-analysis.2020Clinical Genitourinary Cancer
Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses.2020Aging
Efficacy and safety of bevacizumab in progressive pediatric low-grade glioma: a systematic review and meta-analysis of outcome rates.2020Neuro-oncology Practice
Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases.2020Annals of Palliative Medicine
Radiological recurrence patterns after bevacizumab treatment of recurrent high-grade glioma: a systematic review and meta-analysis.2020Korean Journal of Radiology
Efficacy and safety of epidermal growth factor receptor (EGFR) inhibitors plus antiangiogenic agents as first-line treatments for patients with advanced EGFR-mutated non-small cell lung cancer: a meta-analysis.2020Frontiers in Oncology
Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma.2020Medicine
Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis.2020OncoImmunology
Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: a network meta-analysis.2020International Journal of Molecular Sciences
Doublet vs single-agent maintenance therapy in the treatment of non-small-cell lung cancer: a meta-analysis.2020Drug Design, Development and Therapy
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.2020Cochrane Database of Systematic Reviews
Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.2020ESMO Open
The role of maintenance strategies in metastatic colorectal cancer: a systematic review and network meta-analysis of randomized clinical trials.2020JAMA Oncology
A systematic review of systemic treatment options for advanced non-clear cell renal cell carcinoma.2020Kidney Cancer
Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.2020Medicine Open
Systemic bevacizumab (avastin) for juvenile-onset recurrent respiratory papillomatosis: a systematic review.2020The Laryngoscope
First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis.2019BMC Cancer
Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies.2019BMC Cancer
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis.2019Immunotherapy
Baseline serum lactate dehydrogenase level predicts survival benefit in patients with metastatic colorectal cancer receiving bevacizumab as first-line chemotherapy: a systematic review and meta-analysis of 7 studies and 1,219 patients.2019Annals of Translational Medicine
Primary tumor resection in patients with incurable localized or metastatic colorectal cancer: a systematic review and meta-analysis.2019World Journal of Surgery
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature.2019Journal of Neurosurgical Sciences
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: a Bayesian network analysis.2019EBioMedicine
The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: a meta-analysis.2019Medicine Open
Comparative efficacy of preoperative, postoperative, and perioperative treatments for resectable colorectal liver metastases: a network meta-analysis.2019Frontiers in Pharmacology
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.2019BMJ Open
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: a meta-analysis using TRIBE, MAVERICC and FIRE3.2019International Journal of Cancer
Progression-free but no overall survival benefit for adult patients with bevacizumab therapy for the treatment of newly diagnosed glioblastoma: a systematic review and meta-analysis.2019Cancers
Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: a meta-analysis.2019Medicine Open
Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: a meta-analysis.2019Scientific Reports

Clinical Practice Guidelines